Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 24Unknown 6Recruiting 5Terminated 3Withdrawn 2Active not recruiting 2Suspended 1Not yet recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Observational 1Interventional 1

Sponsor

Conditions

Breast Neoplasms 848Carcinoma, Non-Small-Cell Lung 549Neoplasms 510Prostatic Neoplasms 501Lung Neoplasms 312Colorectal Neoplasms 307Multiple Myeloma 292Neoplasm Metastasis 250Melanoma 241Ovarian Neoplasms 215Leukemia, Myeloid, Acute 208Pancreatic Neoplasms 207Squamous Cell Carcinoma of Head and Neck 173Carcinoma, Renal Cell 165Recurrence 162Stomach Neoplasms 161Carcinoma, Hepatocellular 160Lymphoma 156Brain Neoplasms 152Glioblastoma 147Uterine Cervical Neoplasms 144Lymphoma, Non-Hodgkin 141Head and Neck Neoplasms 140Triple Negative Breast Neoplasms 136Leukemia, Lymphocytic, Chronic, B-Cell 136Urinary Bladder Neoplasms 135Precursor Cell Lymphoblastic Leukemia-Lymphoma 132Colonic Neoplasms 115Hematologic Neoplasms 113Lymphoma, Follicular 112

Interventions

Solutions 1Everolimus 1Cannabidiol 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Active not recruiting × Seizures × Clear all
NCT05485831 2026-06-03

EpiTALY

Jazz Pharmaceuticals

Active not recruiting
111 enrolled

Epilepsies, Myoclonic, Seizures, Tuberous Sclerosis, Lennox Gastaut Syndrome

NCT02962414 2026-04-02

Roll-over Study to Collect and Assess Long-term Safety of Everolimus in Patients With TSC and Refractory Seizures Who Have Completed the EXIST-3 Study [CRAD001M2304] and Who Are Benefitting From Continued Treatment

Novartis

Phase 3 Active not recruiting
206 enrolled

Seizures, Tuberous Sclerosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡